For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $2.41 in the last session, down -0.82% from day before closing price of $2.43. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 3.57 million shares were traded. AKBA stock price reached its highest trading level at $2.4488 during the session, while it also had its lowest trading level at $2.34.
Ratios:
We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 28, 2025, initiated with a Outperform rating and assigned the stock a target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Butler John P. sold 46,409 shares for $1.83 per share. The transaction valued at 84,928 led to the insider holds 2,557,921 shares of the business.
Burke Steven Keith sold 7,144 shares of AKBA for $13,074 on Mar 03 ’25. The SVP, Chief Medical Officer now owns 809,090 shares after completing the transaction at $1.83 per share. On Mar 03 ’25, another insider, Burke Steven Keith, who serves as the Officer of the company, bought 7,144 shares for $1.83 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 634791616 and an Enterprise Value of 706175872. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.93. Its current Enterprise Value per Revenue stands at 4.409 whereas that against EBITDA is -81.151.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.87, which has changed by 0.8538462 over the last 52 weeks, in comparison to a change of 0.09969199 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.89, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 21.53%, while the 200-Day Moving Average is calculated to be 37.13%.
Shares Statistics:
According to the various share statistics, AKBA traded on average about 3.95M shares per day over the past 3-months and 2915450 shares per day over the past 10 days. A total of 261.23M shares are outstanding, with a floating share count of 250.51M. Insiders hold about 4.10% of the company’s shares, while institutions hold 23.96% stake in the company. Shares short for AKBA as of 1744675200 were 17922367 with a Short Ratio of 4.54, compared to 1741910400 on 16570902. Therefore, it implies a Short% of Shares Outstanding of 17922367 and a Short% of Float of 6.92.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
